Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Asciminib in Hepatic Impairment
NCT02857868Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- Jul 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of asciminib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Measurable Concentration and 1 more. Started May 2016; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02857868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857868.